Endospan develops and manufactures custom-made endovascular devices for aortic arch treatment, including the NEXUS Aortic Arch Stent Graft System and NEXUS DUO Aortic Arch Stent Graft.

Endospan

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Artivion, Inc.

The NEXUS® Aortic Arch Stent Graft System by Endospan is the only CE-approved off-the-shelf branched endovascular aortic arch system. Indicated for wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, NEXUS® is designed to overcome the specific challenges of the aortic arch anatomy. The NEXUS® “Dock and Lock” modular system provides stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies.

Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan’s NEXUS® Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.

Sequoia Capital Israel

Haisco

Endospan Ltd.

Another successful NEXUS® procedure performed to treat an aortic arch arch aneurysm by the team at the University of Chicago, including Dr. Luka Pocivavsek and Dr. Clayton Brinster, MD, FACS

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Thank you to CARDIOMED SAC, for sharing this great NEXUS® case! 

Learn more about our technology: https://www.endospan.com/
 
CAUTION: Investigational Device - Limited by United States Law to Investigational Use.

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

It takes seamless team collaboration to execute all the details required for a PMA clinical study. This includes expert clinical support at each procedure. Thank you to Cody Barnes, Mario Cosimetti, and Al Calvino, for supporting each TRIOMPHE case with great teamwork and deep clinical expertise. Patients with aortic arch disease benefit from your hard work. 

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Thank you to Dr. James McKinsey, Dr. Rami O. Tadros, MD, FACS, RPVI, Dr. Bert Williams, and Dr. Ismail El-Hamamsy at Icahn School of Medicine at Mount Sinai for their use of NEXUS® to treat a patient with an aortic arch dissection for the TRIOMPHE Study. 

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Another successful NEXUS® procedure performed to treat an aortic dissection by the team at the University of Colorado Department of Surgery, including Dr. T. Brett Reece and Dr. Donald Jacobs. 

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Thank you to the team at the UC San Diego for their recent patient enrollment in the TRIOMPHE study. The NEXUS® System was used to treat a patient with an aortic arch dissection.

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Thank you to Dr. T. Brett Reece, Dr. Muhammad Aftab MD, FACS, FACC     Dr. Donald Jacobs, and the entire team at the University of Colorado Department of Surgery for their recent patient enrollment in the TRIOMPHE study to treat a patient with an aortic arch dissection using the NEXUS® System. 

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Heading to CARDIOVASCULAR INNOVATIONS FOUNDATION in Denver July 18-20? Dr. Sean Crawford  from the University of Toronto will be presenting “Endovascular management of arch lesions with Dual Branch NEXUS Arch Device” on July 19 at during the 10-30-12:00 Ascending Aorta and Arch Session.

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Thank you to Westley Ohman, MD from @Wa for his presentation of the edited live case for the NEXUS® System at #VAM2024. The case demonstrated the use of NEXUS to treat a Type 1A endoleak repair from an aortic aneurysm. 

Learn more about our technology: https://www.endospan.com/

#TRIOMPHEstudy #NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Thank you to Andrew Holden the team at Auckland Regional Public Health Service for performing a recent NEXUS DUO™ procedure to treat a complex dissection. Endospan has recently expanded its portfolio in New Zealand to offer more solutions for Endovascular Aortic Arch Repair.  

Learn more about our technology: https://www.endospan.com/

#NEXUSaorta #totalarch #aorticdissection #aorticaneurysm #aorticarchrepair #aortaEd

Metric
Company Name	Endospan	Artivion, Inc.
Symbol		AORT
MSH ID	COM:ENDOSPAN	COM:ARTIVION
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Medical Devices	Medical - Devices
Country	IL	US
Stage	Debt Financing
Employee Count		1.50K
Website	endospan.com	artivion.com
LinkedIn	endospan
Founders

Metric
Market Cap		1.09B
Enterprise Value
Monthly Web Traffic	293
Web Traffic Growth	-0.25
Valuation
Raised Capital	25M

Metric
Revenue		354.00M
Revenue (LTM)
Revenue (NTM)
Gross Profit		213.98M
EBITDA		37.86M
Operating Income		14.79M
Net Income		-30.57M
EPS		-0.75
Diluted EPS		-0.75
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.65
Operating Profit Margin		0.09
EBITDA Margin		0.11
Net Profit Margin		-0.02
Return on Equity		-0.03
Return on Assets		-0.01
Return on Capital Employed		0.05

ENDO

COM:ENDOSPAN

Endospan

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-27.81
P/B Ratio		2.51
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.18
EV Multiple		138.13

Metric
Days Sales Outstanding		73.35
Days Payables Outstanding		32.70
Days Inventory Outstanding		239.70
Operating Cycle		316.14
Cash Conversion Cycle		277.20
Asset Turnover		0.48

Metric
Operating Cash Flow		18.58M
Free Cash Flow		11.15M
Cash Flow to Debt		0.06
Operating Cash Flow/Sales		0.05
Free Cash Flow Yield		-0.00

Metric
Cash & Equivalents		58.94M
Accounts Receivable		-4.05M
Inventory		81.98M
Goodwill		247.34M
Debt to Capitalization		0.55
Debt to Assets		0.46
Current Ratio		4.86
Quick Ratio		3.16

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.04
R&D to Revenue		0.09
SG&A to Revenue